244 related articles for article (PubMed ID: 8995510)
1. Relationship between pharmacokinetics of unchanged cisplatin and nephrotoxicity after intravenous infusions of cisplatin to cancer patients.
Nagai N; Kinoshita M; Ogata H; Tsujino D; Wada Y; Someya K; Ohno T; Masuhara K; Tanaka Y; Kato K; Nagai H; Yokoyama A; Kurita Y
Cancer Chemother Pharmacol; 1996; 39(1-2):131-7. PubMed ID: 8995510
[TBL] [Abstract][Full Text] [Related]
2. Quantitative relationship between pharmacokinetics of unchanged cisplatin and nephrotoxicity in rats: importance of area under the concentration-time curve (AUC) as the major toxicodynamic determinant in vivo.
Nagai N; Ogata H
Cancer Chemother Pharmacol; 1997; 40(1):11-8. PubMed ID: 9137523
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetics of cisplatin and relation to nephrotoxicity in paediatric patients.
Erdlenbruch B; Nier M; Kern W; Hiddemann W; Pekrun A; Lakomek M
Eur J Clin Pharmacol; 2001 Aug; 57(5):393-402. PubMed ID: 11599657
[TBL] [Abstract][Full Text] [Related]
4. Population pharmacokinetics and pharmacodynamics of cisplatin in patients with cancer: analysis with the NONMEM program.
Nagai N; Ogata H; Wada Y; Tsujino D; Someya K; Ohno T; Masuhara K; Tanaka Y; Takahashi H; Nagai H; Kato K; Koshiba Y; Igarashi T; Yokoyama A; Kinameri K; Kato T; Kurita Y
J Clin Pharmacol; 1998 Nov; 38(11):1025-34. PubMed ID: 9824784
[TBL] [Abstract][Full Text] [Related]
5. Effects of a cisplatin-chondroitin sulfate A complex in reducing the nephrotoxicity of cisplatin.
Zhang JS; Imai T; Otagiri M
Arch Toxicol; 2000 Aug; 74(6):300-7. PubMed ID: 11005675
[TBL] [Abstract][Full Text] [Related]
6. Cisplatin pharmacokinetics and its nephrotoxicity in diabetic rabbits.
Najjar TA; Saad SY
Chemotherapy; 2001; 47(2):128-35. PubMed ID: 11173815
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetics and toxicodynamics of cisplatin and its metabolites in rats: relationship between renal handling and nephrotoxicity of cisplatin.
Hanada K; Ninomiya K; Ogata H
J Pharm Pharmacol; 2000 Nov; 52(11):1345-53. PubMed ID: 11186242
[TBL] [Abstract][Full Text] [Related]
8. Cisplatin pharmacokinetics and pharmacodynamics in patients with squamous-cell carcinoma of the head/neck or esophagus.
Johnsson A; Höglund P; Grubb A; Cavallin-Ståhl E
Cancer Chemother Pharmacol; 1996; 39(1-2):25-33. PubMed ID: 8995496
[TBL] [Abstract][Full Text] [Related]
9. Population Pharmacokinetic-Toxicodynamic Modeling and Simulation of Cisplatin-Induced Acute Renal Injury in Rats: Effect of Dosing Rate on Nephrotoxicity.
Fukushima K; Okada A; Sasaki K; Kishimoto S; Fukushima S; Hamori M; Nishimura A; Shibata N; Shirai T; Terauchi R; Kubo T; Sugioka N
J Pharm Sci; 2016 Jan; 105(1):324-32. PubMed ID: 26852862
[TBL] [Abstract][Full Text] [Related]
10. Therapeutic drug monitoring for dose individualization of Cisplatin in testicular cancer patients based upon total platinum measurement in plasma.
Salas S; Mercier C; Ciccolini J; Pourroy B; Fanciullino R; Tranchand B; Monjanel-Mouterde S; Baciuchka-Palmaro M; Dupuis C; Yang C; Balti M; Lacarelle B; Duffaud F; Durand A; Favre R
Ther Drug Monit; 2006 Aug; 28(4):532-9. PubMed ID: 16885721
[TBL] [Abstract][Full Text] [Related]
11. Effects of disopyramide and verapamil on renal disposition and nephrotoxicity of cisplatin in rats.
Hanada K; Odaka K; Kudo A; Ogata H
Pharm Res; 1999 Oct; 16(10):1589-95. PubMed ID: 10554102
[TBL] [Abstract][Full Text] [Related]
12. [Effects of urinastatin against nephrotoxicity of cisplatinum].
Arakawa A; Kato N; Asai H; Yasui Y; Suzumori K; Suzumori K; Yagami Y
Gan To Kagaku Ryoho; 1990 Nov; 17(11):2229-34. PubMed ID: 2241187
[TBL] [Abstract][Full Text] [Related]
13. [Determination of urinary N-acetyl-beta-D-glucosaminidase (NAG) excretion as a parameter of nephrotoxicity due to cis-platin and the effect of fosfomycin (FOM) on its nephrotoxicity].
Matsuoka R; Inoue T; Miyamura K; Mizutani K; Koike S; Mori H; Kigawa T
Nihon Sanka Fujinka Gakkai Zasshi; 1986 Nov; 38(11):2037-44. PubMed ID: 3794453
[TBL] [Abstract][Full Text] [Related]
14. [Preventive effect of urinastatin on cisplatin-induced nephrotoxicity].
Kobayashi H; Ishizuka H; Hirashima Y; Ohi H; Demukai H; Moniwa M; Maeda M; Kobayashi T; Terao T; Kawashima Y
Nihon Sanka Fujinka Gakkai Zasshi; 1989 Dec; 41(12):1959-64. PubMed ID: 2592819
[TBL] [Abstract][Full Text] [Related]
15. Cisplatin nephrotoxicity in children after continuous 72-h and 3x1-h infusions.
Erdlenbruch B; Pekrum A; Roth C; Grunewald RW; Kern W; Lakomek M
Pediatr Nephrol; 2001 Jul; 16(7):586-93. PubMed ID: 11465809
[TBL] [Abstract][Full Text] [Related]
16. [Comparison of methods for evaluating the nephrotoxicity of cisplatin].
Suzumori K; Yasui Y; Suzumori K; Yagami Y; Seki T
Gan To Kagaku Ryoho; 1988 Aug; 15(8):2251-6. PubMed ID: 3044273
[TBL] [Abstract][Full Text] [Related]
17. Microalbuminuria during cisplatin therapy: relation with pharmacokinetics and implications for nephroprotection.
Kern W; Braess J; Kaufmann CC; Wilde S; Schleyer E; Hiddemann W
Anticancer Res; 2000; 20(5C):3679-88. PubMed ID: 11268439
[TBL] [Abstract][Full Text] [Related]
18. Application of cisplatin as intraoperative hyperthermic peritoneal lavage (IHPL) in patients with locally advanced gastric cancer: analysis of pharmacokinetics and of nephrotoxicity.
Kern W; Braess J; Kotschofsky M; Samel S; Becker H; Hiddemann W; Schleyer E
Anticancer Res; 2002; 22(5):3099-102. PubMed ID: 12530050
[TBL] [Abstract][Full Text] [Related]
19. Effects of sodium thiosulfate on the pharmacokinetics of unchanged cisplatin and on the distribution of platinum species in rat kidney: protective mechanism against cisplatin nephrotoxicity.
Nagai N; Hotta K; Yamamura H; Ogata H
Cancer Chemother Pharmacol; 1995; 36(5):404-10. PubMed ID: 7634382
[TBL] [Abstract][Full Text] [Related]
20. Telmisartan Exacerbates Cisplatin-Induced Nephrotoxicity in a Mouse Model.
Hosoda A; Matsumoto Y; Toriyama Y; Tsuji T; Yoshida Y; Masamichi S; Kohno T
Biol Pharm Bull; 2020; 43(9):1331-1337. PubMed ID: 32879207
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
